A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei

Anthony E. Gregory, Barbara M. Judy, Omar Qazi, Carla A. Blumentritt, Katherine A. Brown, Andrew M. Shaw, Alfredo Torres, Richard W. Titball

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Burkholderia mallei are Gram-negative bacteria, responsible for the disease glanders. B. mallei has recently been classified as a Tier 1 agent owing to the fact that this bacterial species can be weaponised for aerosol release, has a high mortality rate and demonstrates multi-drug resistance. Furthermore, there is no licensed vaccine available against this pathogen. Lipopolysaccharide (LPS) has previously been identified as playing an important role in generating host protection against Burkholderia infection. In this study, we present gold nanoparticles (AuNPs) functionalised with a glycoconjugate vaccine against glanders. AuNPs were covalently coupled with one of three different protein carriers (TetHc, Hcp1 and FliC) followed by conjugation to LPS purified from a non-virulent clonal relative, B. thailandensis. Glycoconjugated LPS generated significantly higher antibody titres compared with LPS alone. Further, they improved protection against a lethal inhalation challenge of B. mallei in the murine model of infection.

Original languageEnglish (US)
Pages (from-to)447-456
Number of pages10
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume11
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Burkholderia mallei
Glycoconjugates
Vaccines
Gold
Nanoparticles
Lipopolysaccharides
Glanders
Pathogens
Antibodies
Aerosols
Bacteria
Burkholderia Infections
Multiple Drug Resistance
Gram-Negative Bacteria
Inhalation
Carrier Proteins
Mortality
Infection
Pharmaceutical Preparations

Keywords

  • Glanders
  • Glycoconjugate
  • Nanoparticles

ASJC Scopus subject areas

  • Molecular Medicine
  • Bioengineering
  • Biomedical Engineering
  • Materials Science(all)
  • Medicine (miscellaneous)
  • Pharmaceutical Science

Cite this

Gregory, A. E., Judy, B. M., Qazi, O., Blumentritt, C. A., Brown, K. A., Shaw, A. M., ... Titball, R. W. (2015). A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei. Nanomedicine: Nanotechnology, Biology, and Medicine, 11(2), 447-456. https://doi.org/10.1016/j.nano.2014.08.005

A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei. / Gregory, Anthony E.; Judy, Barbara M.; Qazi, Omar; Blumentritt, Carla A.; Brown, Katherine A.; Shaw, Andrew M.; Torres, Alfredo; Titball, Richard W.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 11, No. 2, 01.02.2015, p. 447-456.

Research output: Contribution to journalArticle

Gregory, AE, Judy, BM, Qazi, O, Blumentritt, CA, Brown, KA, Shaw, AM, Torres, A & Titball, RW 2015, 'A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei', Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 11, no. 2, pp. 447-456. https://doi.org/10.1016/j.nano.2014.08.005
Gregory, Anthony E. ; Judy, Barbara M. ; Qazi, Omar ; Blumentritt, Carla A. ; Brown, Katherine A. ; Shaw, Andrew M. ; Torres, Alfredo ; Titball, Richard W. / A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2015 ; Vol. 11, No. 2. pp. 447-456.
@article{8a1280d78b3544079f443b334beb9717,
title = "A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei",
abstract = "Burkholderia mallei are Gram-negative bacteria, responsible for the disease glanders. B. mallei has recently been classified as a Tier 1 agent owing to the fact that this bacterial species can be weaponised for aerosol release, has a high mortality rate and demonstrates multi-drug resistance. Furthermore, there is no licensed vaccine available against this pathogen. Lipopolysaccharide (LPS) has previously been identified as playing an important role in generating host protection against Burkholderia infection. In this study, we present gold nanoparticles (AuNPs) functionalised with a glycoconjugate vaccine against glanders. AuNPs were covalently coupled with one of three different protein carriers (TetHc, Hcp1 and FliC) followed by conjugation to LPS purified from a non-virulent clonal relative, B. thailandensis. Glycoconjugated LPS generated significantly higher antibody titres compared with LPS alone. Further, they improved protection against a lethal inhalation challenge of B. mallei in the murine model of infection.",
keywords = "Glanders, Glycoconjugate, Nanoparticles",
author = "Gregory, {Anthony E.} and Judy, {Barbara M.} and Omar Qazi and Blumentritt, {Carla A.} and Brown, {Katherine A.} and Shaw, {Andrew M.} and Alfredo Torres and Titball, {Richard W.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.nano.2014.08.005",
language = "English (US)",
volume = "11",
pages = "447--456",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei

AU - Gregory, Anthony E.

AU - Judy, Barbara M.

AU - Qazi, Omar

AU - Blumentritt, Carla A.

AU - Brown, Katherine A.

AU - Shaw, Andrew M.

AU - Torres, Alfredo

AU - Titball, Richard W.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Burkholderia mallei are Gram-negative bacteria, responsible for the disease glanders. B. mallei has recently been classified as a Tier 1 agent owing to the fact that this bacterial species can be weaponised for aerosol release, has a high mortality rate and demonstrates multi-drug resistance. Furthermore, there is no licensed vaccine available against this pathogen. Lipopolysaccharide (LPS) has previously been identified as playing an important role in generating host protection against Burkholderia infection. In this study, we present gold nanoparticles (AuNPs) functionalised with a glycoconjugate vaccine against glanders. AuNPs were covalently coupled with one of three different protein carriers (TetHc, Hcp1 and FliC) followed by conjugation to LPS purified from a non-virulent clonal relative, B. thailandensis. Glycoconjugated LPS generated significantly higher antibody titres compared with LPS alone. Further, they improved protection against a lethal inhalation challenge of B. mallei in the murine model of infection.

AB - Burkholderia mallei are Gram-negative bacteria, responsible for the disease glanders. B. mallei has recently been classified as a Tier 1 agent owing to the fact that this bacterial species can be weaponised for aerosol release, has a high mortality rate and demonstrates multi-drug resistance. Furthermore, there is no licensed vaccine available against this pathogen. Lipopolysaccharide (LPS) has previously been identified as playing an important role in generating host protection against Burkholderia infection. In this study, we present gold nanoparticles (AuNPs) functionalised with a glycoconjugate vaccine against glanders. AuNPs were covalently coupled with one of three different protein carriers (TetHc, Hcp1 and FliC) followed by conjugation to LPS purified from a non-virulent clonal relative, B. thailandensis. Glycoconjugated LPS generated significantly higher antibody titres compared with LPS alone. Further, they improved protection against a lethal inhalation challenge of B. mallei in the murine model of infection.

KW - Glanders

KW - Glycoconjugate

KW - Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=84922800412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922800412&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2014.08.005

DO - 10.1016/j.nano.2014.08.005

M3 - Article

VL - 11

SP - 447

EP - 456

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 2

ER -